<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="194164">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00564161</url>
  </required_header>
  <id_info>
    <org_study_id>606060-HMO-CTIL</org_study_id>
    <secondary_id>606060-HMO-CTIL</secondary_id>
    <nct_id>NCT00564161</nct_id>
  </id_info>
  <brief_title>VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants</brief_title>
  <official_title>VEGF as a Prognostic Factor for White Matter Damage in Preterm Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We hypothesize that misexpression of vascular endothelial growth factor (VEGF) in the
      Cerebrospinal fluid of preterm infants can be used as a biomarker to predict the risk for
      developing white matter damage.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">January 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Preterm Infants With White Matter Damage</condition>
  <condition>Preterm Infants Developing Normally</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CSF.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        preterm infants.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm infants undergoing lumbar puncture.

        Exclusion Criteria:

          -  Preterm with IVH or known infection or meningitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Weeks</minimum_age>
    <maximum_age>40 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Talya Dor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Organization</affiliation>
  </overall_official>
  <verification_date>November 2007</verification_date>
  <lastchanged_date>September 1, 2016</lastchanged_date>
  <firstreceived_date>November 25, 2007</firstreceived_date>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
